|
|
|
 |
| Location: Home -
Products - Reference Compounds&Impurities - Reference Compounds
|
ICG-001
| Catalogue No. : |
C13753 |
| Product Name: |
ICG-001 |
| Synonym: |
ICG 001;ICG001 |
| Chemical Name: |
(6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-8-(naphthalen-1-ylmethyl)-4,7-dioxooctahydro-1H-pyrazino[1,2-a]pyrimidine-1-carboxamide |
| CAS No. : |
847591-62-2 |
| Structure : |
|
| Molecular Formula: |
C33H32N4O4 |
| Molecular Weight: |
548.63 |
| Solubility: |
Soluble in DMSO |
| Purity: |
99% |
| Usage: |
Specific inhibitor of Wnt/β-catenin signaling pathway; inhibiting β-catenin/cyclic AMP response element-binding (CREB) protein transcription. ICG-001 selectively induces apoptosis in transformed cells but not in normal colon cells, reduces in vitro growth of colon carcinoma cells, and is efficacious in the Min mouse and nude mouse xenograft models of colon cancer. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
